Ocrelizumab - Biogen/Genentech

Drug Profile

Ocrelizumab - Biogen/Genentech

Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; Ocrevus; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec; Genentech
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
  • Class Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Eye-Disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Feb 2018 Health Canada issues conditional approval to ocrelizumab for treatment of Multiple sclerosis (primary progressive)
  • 15 Feb 2018 Adverse events data from the phase III ORATORIO trial in Multiple sclerosis released by Roche
  • 15 Jan 2018 Registered for Multiple sclerosis in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top